New drug for diabetes approved
NICE has approved a drug for treating patients with type 2 diabetes who are intolerant of either metformin, sulphonylurea, thiazolidinediones or dipeptidyl peptidase-4 inhibitors.
Primary care trusts have been ordered by NICE to start funding liraglutide (Victoza), giving 1.2mg daily as a combination treatment. However, it has not approved a 1.8mg dose as the available evidence does not suggest any significant additional benefit.
Online training units, written and reviewed by experts. Earn two hours' CPD and a personalised certificate for your portfolio.
Subscribers get FREE unlimited access to all our online learning units and non-subscribers can access each learning unit for £10 + VAT.